Amino.Desk

FOXO4-DRI

Updated Nov 17, 2026 · Clinical review: pending

FOXO4-DRI is a designed peptide that kills senescent cells, the worn-out cells that build up with age. A 2017 mouse study made it famous. It has never been tested in a person.

What it is

A peptide built from mirror-image amino acids in reverse order, which makes it resist breakdown. It works by separating two proteins, FOXO4 and p53, that keep senescent cells alive. With that bond broken, those cells die. Drugs that do this are called senolytics.

What the evidence shows

The case rests on one 2017 paper in the journal Cell. In aged mice the peptide restored fur density and kidney function. A few later papers have looked at specific tissues in animals.

No human trial has been run or registered. There is no human data on dose, absorption or safety.

Legal status

Reported dosing

We do not publish a protocol for this compound.

No human dose exists. Self-experiment write-ups scale from mouse doses, which is guesswork.

Safety

Common questions

Has FOXO4-DRI been tested in humans?

No. There are no completed or registered human trials.

What did FOXO4-DRI do in mice?

In a 2017 study it cleared senescent cells and restored fur density and kidney function in aged mice.

Is FOXO4-DRI legal?

It is not FDA-approved and is sold only as a research chemical.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy